ArticleFrontiers in pharmacology2025
CCR2 improves tumor directed CAR-T cell trafficking in ovarian cancer.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- In Vivo CAR-Based Immune Cell Engineering: Future Applications and Challenges in Malignant Glioma.Cancers · 2026Review
- Beyond CRISPR: next-gen precision engineering of CAR-NK cells for enhanced persistence, trafficking, and tumor eradication.Cancer cell international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Solid tumors present a significant challenge to Chimeric Antigen Receptor (CAR) -T cell therapy, primarily due to limited T-cell infiltration and persistence in the tumor microenvironment. Cancers with predominantly peritoneal metastasis like ovarian cancer pose a substantial trafficking challenge to systemically administered CAR-T cell therapy. To identify chemokines that may guide CAR-T cells to tumor sites, we evaluated chemokine expression in primary and metastatic tumor samples from patients with ovarian cancer by immunohistochemistry. After identifying CCL2 as the most common chemokine expressed in both primary and metastatic disease, we validated CCL2 levels in serum samples from these patients. We found that CCL2 and CCL4 were commonly expressed in several ovarian cancer cell lines, a patient-derived tumor cell line and patient serum samples
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.